JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

FHS
June 21, 2024
3:52 am

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.

Study reveals new mechanisms involved in the development of inflammatory cardiovascular diseases

A team led by LMU researchers Christian Weber and Yvonne Döring has demonstrated new mechanisms that are involved in the development of inflammatory cardiovascular diseases.

January 24, 2024

Bristol Myers eyes India as home of its largest site outside US by 2025, maps $400M Ireland expansion

Bristol Myers Squibb is making moves on its global facility footprint. “Here’s one I hear a lot: Innovation comes mainly from the US. But clearly,

February 29, 2024

Opinion | Can Dying Shopping Malls Fix Medical Deserts?

Lewiss is a professor of emergency medicine and a healthcare designer. Del Rios is an associate professor of emergency medicine and a health services researcher.

March 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.